semaglutide vs tirzepatide vs liraglutide vs. Semaglutide: What You Should Know Tirzepatide vs semaglutide and liraglutide

Madrigals second Phase 3 study, MAESTRO-NAFLD-1, was initiated at the end of 2019 and is expected to enroll 700 patients with early stages of the disease (NAFLD or presumed NASH)

Orforglipron (branded as Foundayo) is the first small molecule GLP-1 receptor agonist, distinguishing it from peptide-based options like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound)

This results in a lower ability to promote receptor internalization compared with endogenous GLP-1, so it allows to have an increased GLP-1R expression on the cell surface, which translates in more robust insulinotropic properties, possibly explaining the enhanced insulin secretion (in both diabetic and not diabetic human islets), induced by TZP (19) by approximately 25% more than the one induced by only one of the two agents

Another acceptable injection site is the upper arm (specifically the back of the arm), as it also provides enough fatty tissue for proper absorption

The following labs are the minimum reasonable panel: IGF-1 (serum): Baseline, 8 weeks into cycle, 4 weeks post-cycle

Patient safety issues in the GLP-1 space this week Post found on Reddit, March 2025 GLP-1s are revolutionary medicines that can make a huge difference in the lives of diabetics and people suffering from obesity, but they come with significant side effects and must be prescribed by a doctor